Minerva Neurosciences, Inc. (NERV) Stock Forecast
Data as of Sep 20, 2026Healthcare · Current price $3.52 (+1.59%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
NERV vs Sector & Market
| Metric | NERV | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.25 | 2.42 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | +184.5% | +22243.5% | +21.5% |
| P/E Ratio | -0.24 | 3.76 | 38.34 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $20M | $20M | $20M | 2 |
| 2027-12-31 | $56M | $56M | $56M | 2 |
| 2028-12-31 | $19M | $19M | $19M | 2 |
| 2029-12-31 | $81M | $81M | $81M | 1 |
| 2030-12-31 | $221M | $221M | $221M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.73 | $-0.73 | $-0.73 | 1 |
| 2027-12-31 | $-0.62 | $-0.62 | $-0.62 | 1 |
| 2028-12-31 | $-0.44 | $-0.36 | $-0.29 | 2 |
| 2029-12-31 | $0.10 | $0.10 | $0.10 | 1 |
| 2030-12-31 | $0.88 | $0.88 | $0.88 | 1 |
Frequently Asked Questions
What is the analyst consensus for NERV?
The consensus among 1 analysts covering Minerva Neurosciences, Inc. (NERV) is Hold with an average price target of $10.00.
What is the highest price target for NERV?
The highest analyst price target for NERV is $10.00.
What is the lowest price target for NERV?
The lowest analyst price target for NERV is $10.00.
How many analysts cover NERV?
1 analysts have issued ratings for Minerva Neurosciences, Inc. in the past 12 months.
Is NERV a buy or sell right now?
Based on 1 analyst ratings, NERV has a consensus rating of Hold (3.00/5) with a +184.5% upside to the consensus target of $10.00.
What are the earnings estimates for NERV?
Analysts estimate NERV will report EPS of $-0.73 for the period ending 2026-12-31, with revenue estimated at $20M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.